ERBB2 and breast carcinoma: The reason of exclusions from several cohort studies is that the number of ER−/PR− cases was relatively small; the statistical power was insufficient to assess other relevant breast cancer subtypes, such as triple negative, or HER2-positive (Zhang et al. 2013).